KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Income from Continuing Operations (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Income from Continuing Operations readings, the most recent being 245845000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 1017.5% to 245845000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 263861000.0, a 396.87% increase, with the full-year FY2025 number at 263861000.0, up 396.87% from a year prior.
  • Income from Continuing Operations hit 245845000.0 in Q4 2025 for Biocryst Pharmaceuticals, up from 12899000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 245845000.0 in Q4 2025 to a low of 75326000.0 in Q2 2023.
  • Median Income from Continuing Operations over the past 5 years was 39334500.0 (2022), compared with a mean of 24136850.0.
  • Biggest five-year swings in Income from Continuing Operations: crashed 302.39% in 2022 and later skyrocketed 1017.5% in 2025.
  • Biocryst Pharmaceuticals' Income from Continuing Operations stood at 17779000.0 in 2021, then plummeted by 302.39% to 71541000.0 in 2022, then grew by 13.71% to 61731000.0 in 2023, then skyrocketed by 56.59% to 26795000.0 in 2024, then skyrocketed by 1017.5% to 245845000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 245845000.0 (Q4 2025), 12899000.0 (Q3 2025), and 5085000.0 (Q2 2025) per Business Quant data.